Antibody-Drug Conjugate (ADC) sequencing on treatment outcomes in Breast Cancer

Four real-world data studies looked to understand the impact of ADC sequencing on treatment outcomes in Breast Cancer (BC).

Acknowledging data limitations, there appears to be a consensus that median time to progression likely decreases for a 2nd ADC.

However, the optimal order of Trodelvy and T-DXd remains unclear with authors hypothesizing that outcomes likely are driven by patient characteristics, further demonstrating the need for well controlled, prospective studies to provide definitive data on this topic and to support optimal patient and treatment selection

The discussant also highlighted that the TBCRC (Translational Breast Cancer Research Consortium) has created a registry to capture data on sequential ADC usage in HER2-low mBC as well as sponsoring TRADE-DXD a randomized P2 study investigating the optimal sequence of T-DXd and Dato-DXd in HER2 low mBC.

source: SABCS 2023